Mesoblast's MPCs clear interim heart failure hurdle

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said an independent DMC recommended continuation of a Phase III trial of chronic heart failure (CHF) candidate MPC-150-IM following an interim futility analysis of an efficacy endpoint evaluating non-fatal cardiac events. The analysis included the first 270 of a planned 600 patients with moderate to advanced CHF with left ventricular systolic dysfunction.

Mesoblast gained A$0.24 (10%) to A$2.67 in Sydney on Monday. It added $0.64 to $10.19 on NASDAQ...